DASH
Repository logo
Communities & Collections
Browse DASH
DASH Stories
Statistics
  1. Home
  2. Faculty of Arts and Sciences
  3. FAS Theses and Dissertations
  4. Rational Design of Selective Protein Therapeutics for Structurally and Functionally Complex Targets

Rational Design of Selective Protein Therapeutics for Structurally and Functionally Complex Targets

Open/View files
Doiron_2025_DAC_Thesis_Combined_Final.pdf (6.77 MB)
Date
May 8, 2025
Author(s)
Doiron, Kailyn
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Doiron, Kailyn. 2025. Rational Design of Selective Protein Therapeutics for Structurally and Functionally Complex Targets. Doctoral Dissertation, Harvard University Graduate School of Arts and Sciences.
Abstract
Protein biologics have transformed modern drug discovery and development by offering high selectivity and reduced off-target effects, prolonged serum half-lives, and the ability to modulate cellular processes. However, many clinically relevant targets remain intractable due to limited structural or mechanistic information, selectivity issues, or the need to modulate multiple pathways simultaneously. This work presents two distinct case studies in engaging challenging targets using rationally designed bispecific protein therapeutics and Fc fusion proteins. In Chapter 1, I describe the successful design and characterization of the first non-EPO-based, bispecific agonists for the tissue-protective receptor, EPO-R/CD131. We generated a structural model of the EPO-R/CD131 complex using AlphaFold and available structures of EPO-R and CD131 individually bound to single chain variable fragments (scFvs). Using this model, we designed several tandem scFvs and a bispecific antibody that selectively activated EPO-R/CD131 and not the related receptor, EPO-R/EPO-R. These proteins serve as a foundation for future studies of EPO-R/CD131 biology or for the development of safer, more selective therapeutic candidates for cell-protection applications, such as neurodegenerative diseases. In Chapter 2, I detail the design and early stage testing of several mono- and bi-specific Fc fusion proteins for the treatment of dysfunctional and inflammatory pain. Using similar design principles, I generated Fc fusions to peptides that inhibit the voltage-gated sodium channels Nav1.7 and Nav1.8 and Fc fusions to neprilysin, an enzyme that degrades the neuroinflammatory peptide, substance P. Altogether, this work provides novel approaches to the modulation of these challenging targets and insights about future design considerations and possible solutions to further the development of protein therapeutics for cell-protection and chronic pain.
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service
URI
https://dash.harvard.edu/handle/1/42719727
Subjects

Erythropoietin

Fc fusion

Fusion proteins

Protein engineering

scFv

Synthetic Biology

Bioengineering

Molecular biology

Pharmaceutical scienc...

Collection
FAS Theses and Dissertations
Metrics
Repository logo
  • CONTACT US
  • OSRDS
  • ABOUT DASH
  • DEPOSITING TO DASH
  • TERMS OF USE
  • REQUEST A WAIVER
  • TAKE DOWN POLICY
  • NAME CHANGE POLICY
  • HARVARD OA POLICIES
  • DASH SUBMITTER AGREEMENT
  • Accessibility
  • Privacy
Creative Commons License BY
Creative Commons Attribution 4.0 International License

Except where otherwise noted, this work is subject to a Creative Commons Attribution 4.0 International License,
which allows anyone to share and adapt our material as long as proper attribution is given.
For details and exceptions, see the Harvard Library Copyright Policy
©2024 Presidents and Fellows of Harvard College.